Validation of the SMART-REACH model after stroke and the effect of colchicine by atherosclerotic cardiovascular disease risk category: a secondary analysis of the CONVINCE randomised clinical trial
European Stroke Journal · 2026
DOI: 10.1093/esj/aakag033 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Stroke Journal, 2026. Verfasst von Louise Maes und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospitals Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Colchicine, Atherosclerosis, Stroke, Ischemic Attack, Transient. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Fonds Wetenschappelijk Onderzoek Vlaanderen.
Themen: Schlaganfall
Abstract (Originalsprache)
Introduction
The Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) trial showed that recurrent events were significantly reduced among colchicine-adherent non-cardioembolic stroke patients in the on-treatment analysis. This study aimed to validate the SMART-REACH risk score in stroke patients, and to determine whether colchicine’s efficacy varies by baseline atherosclerotic cardiovascular disease (ASCVD) risk. Patients and methods Patients with non-severe non-cardioembolic ischaemic stroke/transient ischaemic attack (TIA) were randomised to colchicine 0.5 mg plus usual care or usual care alone. Participants were stratified into moderate (10%–19%), high (20%–30%) and very high (≥30%) 10-year ASCVD risk categories using the SMART-REACH model. Model performance was assessed using the C-statistic and calibration plots. The primary endpoint (major adverse cardiovascular events [MACE]) was a composite of fatal or non-fatal recurrent ischaemic stroke, myocardial infarction, cardiac arrest or hospitalisation for unstable angina.
Results
Among 3144 patients, MACE incidence significantly increased with ASCVD risk levels: 7.2% (moderate), 8.8% (high) and 13.8% (very high) (P < .01). The C-statistic for 3-year risk of MACE was 0.59 (95% CI, 0.56–0.63). While no statistically significant treatment interaction was found (P = .88), absolute risk reductions (ARRs) were more pronounced in higher-risk groups: moderate risk 7.2% (colchicine) vs 7.2% (usual care) (hazard ratio [HR] 1.01; 95% CI, 0.55–1.83); high risk 7.7% vs 9.8% (ARR 2.1%; HR 0.79; 95% CI, 0.53–1.18); very high risk 12.5% vs 15.2% (ARR 2.7%; HR 0.85; 95% CI, 0.64–1.12). Discussion and Conclusion We identified an association between very high baseline ASCVD risk (≥30%) assigned by the SMART-REACH score and increased recurrent MACE. Although no significant treatment interaction was observed, patients in higher risk categories may represent a more promising target population for secondary prevention with colchicine. Trial Registration ClinicalTrials.gov Identifier: NCT02898610.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
- Department of Neurosciences, Experimental Neurology, KU Leuven - University of Leuven, Leuven, Belgium.
- TCD Biostatistics Unit, Discipline of Public Health and Primary Care, School of Medicine, Trinity College Dublin, Dublin, Ireland.
- BDH-Clinic Elzach, Elzach, Germany.
- Institute for Medical Informatics, Biometry and Epidemiology, University Hospital, University Duisburg-Essen, Essen, Germany.
- Stroke Unit, Department of Neurology, Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain.
ORCID-Profile: Louise Maes, Cathal Walsh, Francisco Purroy, Christopher Price, Catarina Fonseca, Michael D Hill, Dalius Jatuzis, Janika Kõrv, Christina Kruuse, Robert Mikulik, Paul Nederkoorn, Anna Czlonkowska, Urs Fischer, Michael McCormick, Maria Castellanos, João Pedro Marto, David J Williams, Peter Kelly, Robin Lemmens
Förderung
- Deutsche Forschungsgemeinschaft
- Fonds Wetenschappelijk Onderzoek Vlaanderen
Zitieren
APA
Maes, L., Verschuere, C., Walsh, C., Weimar, C., Purroy, F., Price, C., Fonseca, C., Hill, M. D., Jatuzis, D., Kõrv, J., Kruuse, C., Mikulik, R., Nederkoorn, P., Czlonkowska, A., Fischer, U., McCormick, M., Castellanos, M., Baptista, M., Marto, J. P., …, & CONVINCE investigators (2026). Validation of the SMART-REACH model after stroke and the effect of colchicine by atherosclerotic cardiovascular disease risk category: a secondary analysis of the CONVINCE randomised clinical trial. European Stroke Journal. https://doi.org/10.1093/esj/aakag033
Vancouver
Maes L, Verschuere C, Walsh C, Weimar C, Purroy F, Price C, et al. Validation of the SMART-REACH model after stroke and the effect of colchicine by atherosclerotic cardiovascular disease risk category: a secondary analysis of the CONVINCE randomised clinical trial. European Stroke Journal. 2026. doi:10.1093/esj/aakag033
BibTeX
@article{Maes2026,
author = {Maes, Louise and Verschuere, Claudia and Walsh, Cathal and Weimar, Christian and Purroy, Francisco and Price, Christopher and Fonseca, Catarina and Hill, Michael D and Jatuzis, Dalius and Kõrv, Janika and Kruuse, Christina and Mikulik, Robert and Nederkoorn, Paul and Czlonkowska, Anna and Fischer, Urs and McCormick, Michael and Castellanos, Maria and Baptista, Miguel and Marto, João Pedro and Thavanesan, Kamy and Williams, David J and Kelly, Peter and Lemmens, Robin and CONVINCE investigators, CONVINCE investigators},
title = {Validation of the SMART-REACH model after stroke and the effect of colchicine by atherosclerotic cardiovascular disease risk category: a secondary analysis of the CONVINCE randomised clinical trial},
journal = {European Stroke Journal},
year = {2026},
doi = {10.1093/esj/aakag033}
}
EUVIMED